The FDA has granted Scholar Rock's apitegromab fast track designation for the treatment of patients with living facioscapulohumeral muscular dystrophy as the company's phase 2 FORGE study dosing begins.
|Videos|May 28, 2020
CMSC 2020 Day 3: Laura Safar, MD on Use of Psychotropics in MS
Author(s)NeurologyLive® Staff
Laura Safar, MD, presents her lecture titled, "Use of Psychotropics in MS: Antidepressants, Anti-anxiety Agents, Mood Stabilizers, Hypnotics, Antipsychotics, and Cognitive Enhancers" as part of the 2020 CMSC Virtual Annual Meeting.
Advertisement
For more coverage from CMSC 2020,
To register for the 2020 CMSC Virtual Annual Meeting, May 26-29, 2020,
To complete the evaluation and claim credit, go to
Advertisement
Related to this article
Tonic motor activation therapy was associated with reductions in RLS severity, along with tolerable reductions in dopamine agonist dosing, in adults with medication-refractory RLS.
A migraine forecasting model achieved 91% precision using app data, but the study did not test whether next-day predictions improve care.
The professor of neurology at the University of Cincinnati discussed why disparities persist in secondary stroke prevention and how growing awareness of social determinants of health is helping to close the gap for underserved patients.
In recognition of World Alzheimer's Day, NeurologyLive reviews Alzheimer disease developments from 2026, spanning blood-based biomarkers, emerging treatments, prevention research, disease risk factors, and safety considerations surrounding anti-amyloid therapies.
The positive opinion for intravenous ocrelizumab was supported by phase 3 OPERETTA 2 findings demonstrating noninferior relapse control and superior suppression of MRI-detected brain lesions compared with fingolimod in pediatric patients with relapsing MS.
The FDA lifted a clinical hold on simufilam, clearing Filana Therapeutics, formerly Cassava Sciences, to begin a phase 2a study in TSC-related epilepsy.
Ulefnersen met its primary end point in the phase 3 FUSION trial, providing the first placebo-controlled evidence for a genetically targeted therapy in FUS-ALS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Ulefnersen Meets Primary End Point in Phase 3 FUSION Trial for FUS-ALS
2
From Biomarkers to Prevention: Key Alzheimer Research Stories of 2026
3
Qihuang Needle Acupuncture Improves Motor and Nonmotor Parkinson Disease Symptoms
4
Group-Based Resilience Program Improves Psychological Outcomes in Multiple Sclerosis
5